Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Field Trials

2 Oct 2008 07:52

RNS Number : 9078E
Plant Health Care PLC
02 October 2008
 



2 October 2008

 

Plant Health Care plc

("Plant Health Care" or "the Company")

IMPRESSIVE YIELD GAINS FROM SOUTH AFRICAN HARPIN TRIALS

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that independent trials of a Harpin based treatment, on commercial potato production in South Africa, have resulted in significant yield gains compared to conventional chemical treatments. 

The comparison trials were undertaken in South Africa, by Bayagro, an important distributor to the potato industry, and presented to the Potato Seed Council of South Africa to show the efficacy of 20 combination chemical and natural potato treatments. This trial was conducted to establish a new 'best practice' for potato growing in South Africa. 

The results showed that a Harpin based product, when used in conjunction with a standard treatment, yielded 8.1% more than all other treatments, including the current industry standard. These results have established Harpin as the new standard treatment for potato production in South Africa.

As a result of these successful trials Jason Holohan, Managing Director of UK/Spain, was invited as a guest speaker to address the recent annual South African Seed Potato Growers Forum. This forum represents growers from the potato industry in South Africa which harvests over 60,000 hectares.

John Brady, CEO of Plant Health Care commented, "South Africa represents a new and exciting market for PHC. As a result of Jason's initiative in this market and the resultant successful trials we have received significant orders for the remainder of the 2008 season as well as for 2009. We now have a strong distributor in this market and look forward to initiating sales into a variety of crops with both Harpin and Myconate."

- ends -

For Further Information:

John Brady

Evolution Securities Limited

Tavistock Communications

Chief Executive

Tim Worlledge/Tim Redfern

Jeremy Carey/Simon Compton

Tel: 001 603 525 3702

Tel: 020 7071 4300

Tel: 020 7920 3150

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAKEAESEPFEE
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.